Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Diarrhea × capivasertib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Exanthema 1 Diarrhea 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1 Advanced Gastric Cancer 1 Advanced Breast Cancer 1 Adenocarcinoma 1

Interventions

Octreotide 2 telotristat ethyl 1 isatuximab 1 ceterizine hydrochloride 1 capivasertib 1 cabazitaxel 1 XRP6258 1 Prednisone 1 Loperamide 1 Leucovorin 1 Lapatinib 1 Irinotecan 1 Injections 1 Granulocyte Colony-Stimulating Factor 1 Fulvestrant 1 Fluorouracil 1 Filgrastim 1 Drugs, Investigational 1 Cyclophosphamide 1 Colesevelam Hydrochloride 1 Cell- and Tissue-Based Therapy 1 Capecitabine 1 Calcium Aluminosilicate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07426822 2026-02-24

SAFE-CAP

Yale University

Phase 2 Not yet recruiting

Diarrhea, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡